Nasdaq: XENT

Intersect ENT, Inc.

Intersect ENT’s mission is to advance clinically proven therapy solutions that enable ear, nose, and throat (ENT) physicians to solve clinical challenges and improve the quality of life for patients.

Located in Menlo Park, CA, Intersect ENT’s initial focus is chronic sinusitis, a condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain. For these chronic sinus sufferers, their condition deeply impacts their quality of life and often requires a complex combination of medical and surgical therapy. While surgical solutions relieve symptoms in many patients, disease can recur even in the postoperative period; the majority have symptoms that persist within the first year. At Intersect ENT they believe there had to be a better way — to improve both the patient experience and surgical outcomes as well as alleviate physician frustration with disease recurrence. They have developed the PROPEL steroid-releasing implant with these goals in mind.